Enovis Announces Appointment of Damien McDonald as Chief Executive Officer
Enovis (NYSE: ENOV) has announced the appointment of Damien McDonald as its new Chief Executive Officer, effective May 12, 2025. McDonald, who brings over 35 years of medical device industry experience, will succeed Matt Trerotola, who is retiring. McDonald will also join the Enovis Board of Directors after the 2025 Annual Meeting on May 21.
McDonald previously served as CEO of LivaNova, where he improved growth, profitability, and shareholder value. His experience includes leadership roles at Danaher, Zimmer, and Johnson & Johnson's Ethicon unit. The company has reiterated its Q1 2025 guidance with expected revenues of $555-563 million and adjusted EBITDA of $97-100 million.
Sharon Wienbar, currently Lead Independent Director, will become Board Chair following Trerotola's retirement. The company will address questions about the transition during its Q1 2025 earnings call on May 8, 2025.
Enovis (NYSE: ENOV) ha annunciato la nomina di Damien McDonald come nuovo Amministratore Delegato, con effetto dal 12 maggio 2025. McDonald, che porta con sé oltre 35 anni di esperienza nel settore dei dispositivi medici, succederà a Matt Trerotola, che si ritira. McDonald entrerà anche a far parte del Consiglio di Amministrazione di Enovis dopo l'Assemblea Annuale del 2025, che si terrà il 21 maggio.
In precedenza, McDonald ha ricoperto il ruolo di CEO di LivaNova, dove ha migliorato la crescita, la redditività e il valore per gli azionisti. La sua esperienza include ruoli di leadership presso Danaher, Zimmer e la divisione Ethicon di Johnson & Johnson. L'azienda ha ribadito le previsioni per il primo trimestre del 2025, con ricavi attesi tra 555 e 563 milioni di dollari e un EBITDA rettificato compreso tra 97 e 100 milioni di dollari.
Sharon Wienbar, attualmente Direttore Indipendente Principale, diventerà Presidente del Consiglio dopo il ritiro di Trerotola. L'azienda affronterà le domande riguardanti la transizione durante la chiamata sugli utili del primo trimestre del 2025, prevista per l'8 maggio 2025.
Enovis (NYSE: ENOV) ha anunciado el nombramiento de Damien McDonald como su nuevo Director Ejecutivo, efectivo a partir del 12 de mayo de 2025. McDonald, que aporta más de 35 años de experiencia en la industria de dispositivos médicos, sucederá a Matt Trerotola, quien se retira. McDonald también se unirá a la Junta Directiva de Enovis después de la Junta Anual de 2025, que se celebrará el 21 de mayo.
McDonald fue anteriormente CEO de LivaNova, donde mejoró el crecimiento, la rentabilidad y el valor para los accionistas. Su experiencia incluye roles de liderazgo en Danaher, Zimmer y la unidad Ethicon de Johnson & Johnson. La empresa ha reiterado su guía para el primer trimestre de 2025, con ingresos esperados de entre 555 y 563 millones de dólares y un EBITDA ajustado de entre 97 y 100 millones de dólares.
Sharon Wienbar, actualmente Directora Independiente Principal, se convertirá en Presidenta de la Junta tras la jubilación de Trerotola. La empresa abordará preguntas sobre la transición durante su llamada de resultados del primer trimestre de 2025, programada para el 8 de mayo de 2025.
Enovis (NYSE: ENOV)는 Damien McDonald을 새로운 CEO로 임명했다고 발표했습니다. 그는 2025년 5월 12일부터 취임합니다. McDonald는 35년 이상의 의료기기 산업 경험을 가지고 있으며, 은퇴하는 Matt Trerotola를 대신하게 됩니다. McDonald는 2025년 5월 21일에 열리는 연례 회의 이후 Enovis 이사회에도 합류할 예정입니다.
McDonald는 LivaNova의 CEO로 재직하면서 성장, 수익성 및 주주 가치를 향상시켰습니다. 그의 경력에는 Danaher, Zimmer 및 Johnson & Johnson의 Ethicon 부서에서의 리더십 역할이 포함됩니다. 회사는 2025년 1분기 매출 예상치를 5억 5천 5백만 달러에서 5억 6천 3백만 달러, 조정 EBITDA는 9천 7백만 달러에서 1억 달러로 재확인했습니다.
현재 독립 이사장인 Sharon Wienbar는 Trerotola의 은퇴 후 이사회 의장이 될 것입니다. 회사는 2025년 5월 8일에 예정된 2025년 1분기 실적 발표 전화 회의에서 전환에 대한 질문을 다룰 것입니다.
Enovis (NYSE: ENOV) a annoncé la nomination de Damien McDonald en tant que nouveau Directeur Général, à compter du 12 mai 2025. McDonald, qui possède plus de 35 ans d'expérience dans l'industrie des dispositifs médicaux, succédera à Matt Trerotola, qui prend sa retraite. McDonald rejoindra également le Conseil d'Administration d'Enovis après l'Assemblée Générale Annuelle de 2025, qui se tiendra le 21 mai.
Auparavant, McDonald était PDG de LivaNova, où il a amélioré la croissance, la rentabilité et la valeur pour les actionnaires. Son expérience comprend des postes de direction chez Danaher, Zimmer et la division Ethicon de Johnson & Johnson. L'entreprise a réitéré ses prévisions pour le premier trimestre 2025, avec des revenus attendus entre 555 et 563 millions de dollars et un EBITDA ajusté entre 97 et 100 millions de dollars.
Sharon Wienbar, actuellement Directrice Indépendante Principale, deviendra Présidente du Conseil après le départ à la retraite de Trerotola. L'entreprise répondra aux questions concernant la transition lors de sa conférence téléphonique sur les résultats du premier trimestre 2025, prévue pour le 8 mai 2025.
Enovis (NYSE: ENOV) hat die Ernennung von Damien McDonald zum neuen CEO bekannt gegeben, die am 12. Mai 2025 in Kraft tritt. McDonald bringt über 35 Jahre Erfahrung in der Medizintechnikbranche mit und wird Matt Trerotola nachfolgen, der in den Ruhestand geht. McDonald wird nach der Jahreshauptversammlung 2025 am 21. Mai auch dem Vorstand von Enovis beitreten.
Vor seiner Ernennung war McDonald CEO von LivaNova, wo er das Wachstum, die Rentabilität und den Aktionärswert verbesserte. Zu seinen Erfahrungen zählen Führungspositionen bei Danaher, Zimmer und der Ethicon-Einheit von Johnson & Johnson. Das Unternehmen hat seine Prognose für das erste Quartal 2025 mit erwarteten Einnahmen von 555 bis 563 Millionen Dollar und einem bereinigten EBITDA von 97 bis 100 Millionen Dollar bekräftigt.
Sharon Wienbar, derzeit unabhängige Hauptdirektorin, wird nach Trerotolas Ruhestand Vorsitzende des Vorstands. Das Unternehmen wird während der Telefonkonferenz zu den Ergebnissen des ersten Quartals 2025 am 8. Mai 2025 Fragen zur Übergabe beantworten.
- Appointment of experienced CEO with 35+ years in medical device industry
- Strong Q1 2025 guidance with revenues of $555-563M and adjusted EBITDA of $97-100M
- New CEO's proven track record of improving growth and profitability at LivaNova
- Departure of current CEO Matt Trerotola could create temporary leadership transition uncertainty
- Damien McDonald appointed CEO, effective as of May 12, 2025
- Company reiterates guidance for first quarter revenues and aEBITDA
WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “The Company”) (NYSE: ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company’s 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at the Annual Meeting. Enovis also reiterated its expectations for first quarter revenues to be in the range of
Sharon Wienbar, Lead Independent Director at Enovis, stated, “On behalf of the Board, I am thrilled to welcome Damien to the Enovis team. The Board of Directors, with the assistance of a leading executive search firm, carefully identified, evaluated and interviewed highly qualified candidates and Damien stood out. His strong track record as CEO of a public, global medical technology combined with his long history of relevant business successes and his similar approach to business processes and culture make him the right leader for Enovis at this stage in our growth journey.”
Mr. McDonald joins Enovis with more than 35 years of experience in the medical device industry. Most recently, he served as CEO of LivaNova, a global business creating clinically differentiated medical devices for the head and heart to improve the lives of patients worldwide. In his six years there, he drove improved results in growth, profitability and shareholder value. He also made a meaningful impact on company culture, centered on a ‘Patients First’ mindset. Earlier in his career, he was a Group Executive and Corporate Vice President leading a
"I am honored to join the Enovis team at this exciting time in the Company’s history and to have the opportunity to lead the Company into its next phase of growth,” says Mr. McDonald. “I share the Company’s vision of developing innovative technologies to improve patient outcomes and I look forward to building upon Enovis’ strong foundation and delivering exceptional value for all of our stakeholders.”
Mr. Trerotola said, “Damien has the experience, track record, and cultural fit to be a fantastic next leader of Enovis. I am grateful for the opportunity to lead Colfax and Enovis for the past decade and look forward to a smooth transition that continues to build on the Company’s great operational and strategic momentum.”
Enovis also announced that Ms. Wienbar will assume the role of independent Chair of the Board following Mr. Trerotola’s retirement at the Annual Meeting. The Company will take questions regarding the management transition plan on its first quarter 2025 earnings call scheduled for May 8, 2025, at 8:30 a.m. ET.
About Enovis
Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company’s shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit www.enovis.com.
Availability of Information on the Enovis Website
Investors and others should note that Enovis routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Enovis Investor Relations website. While not all of the information that the Company posts to the Enovis Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in Enovis to review the information that it shares on ir.enovis.com.
Forward-Looking Statements
This press release includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis’ plans, goals, objectives, outlook, expectations and intentions, and other statements that are not historical or current fact. Forward-looking statements are based on Enovis’ current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Enovis’ results to differ materially from current expectations include, but are not limited to, risks related to the impact of public health emergencies and global pandemics (including COVID-19); disruptions in the global economy caused by escalating geopolitical tensions including in connection with Russia’s invasion of Ukraine; macroeconomic conditions, including the impact of inflationary pressures; supply chain disruptions; increasing energy costs and availability concerns, particularly in the European market; other impacts on Enovis’ business and ability to execute business continuity plans; and the other factors detailed in Enovis’ reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors,” as well as the other risks discussed in Enovis’ filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This press release speaks only as of the date hereof. Enovis disclaims any duty to update the information herein.
Kyle Rose
Vice President, Investor Relations
Enovis Corporation
investorrelations@enovis.com
FAQ
When will Damien McDonald take over as CEO of Enovis (ENOV)?
What is Enovis (ENOV) Q1 2025 revenue guidance?
What is Damien McDonald's previous experience before joining Enovis (ENOV)?
Who will become the Board Chair of Enovis (ENOV) after the transition?
